Nkarta Inc (NKTX)

[jondoeuk]

Program three (another CAR-NK) is for CD70+ types. Based on immunohistochemistry, and for hematological malignancies, it is expressed (levels vary) on different non-Hodgkin lymphoma's (including T-cell types), Hodgkin lymphoma's, some leukaemia's and multiple myeloma.

For solid tumours, renal cell carcinoma (mostly clear cell, but also papillary, chromophobe, oncocytomas and sarcomatoid), glioblastoma, astrocytoma, nasopharyngeal (EBV associated), mesothelioma, HCC, esophagus, pancreatic, CRC, breast, ovarian, thyroid, NSCLC (mostly neuro-endocrine, but also adenocarcinoma and squamous), and melanoma.